In a 60-second interview with PharmaSource, Jürgen Wagner, the newly appointed General Manager of Ophtapharm AG, outlined his vision for the Swiss contract manufacturing organization as it enters a new phase of growth in sterile ophthalmic manufacturing.
Jürgen, who took the helm in July 2025, brings more than 20 years of pharmaceutical operations experience from senior roles at Baxter and Takeda, where he specialized in aseptic and sterile manufacturing across European and Asian markets.
“I am really excited to join Ophtapharm as General Manager,” Jürgen said. “I bring with me more than 20 years of experience in pharmaceutical operations in aseptic and sterile manufacturing.”
Ophtapharm, a Sentiss Company, operates as a contract development and manufacturing organization specializing in sterile pharmaceutical products. The company leverages 40 years of expertise in Swiss-quality manufacturing, with facilities designed to meet stringent US market requirements.
The company’s state-of-the-art manufacturing facility focuses on ophthalmic, otic, and topical products, serving pharmaceutical companies requiring specialized sterile manufacturing capabilities across multiple global markets.
Strategic Focus on End-to-End Services
Under Jürgen’s leadership, Ophtapharm will focus on expanding its comprehensive manufacturing capabilities. The company offers end-to-end expertise covering process transfers, analytical development, formulation services, material and inventory management, production testing, and global product release.
“Ophtapharm offers end-to-end expertise in process transfers. We deliver successful process in analytical transfers with full support across formulation and analytical development material and inventory management and production testing and global product release,” Jürgen explains.
The appointment comes as Ophtapharm, now part of the Sentiss Group, enters what Jürgen describes as “an exciting new chapter as CDMO in the ophthalmic space.”
Manufacturing Capabilities and Market Position
Ophtapharm operates as an FDA-approved facility serving customers across North America, Europe, and global markets. The company specializes in sterile production of solutions, suspensions, emulsions, ointments, and gels for ophthalmic, otic, and topical applications.
The company’s Swiss location provides strategic advantages in accessing international pharmaceutical markets. “Switzerland is a renowned international pharmaceutical hub that gives Ophtapharm the benefit of access to world class talent, cutting edge infrastructure, and a stable innovation driven environment,” Jürgen notes.
